{"schema_version":"secwatch.filing_event.v1","accession":"0001801170-24-000101","form_type":"8-K","ticker":"CLOV","cik":"0001801170","company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.182853+00:00","generated_at":"2026-06-02T19:38:26.522461+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Clover Health Q1 2024: first Adj. EBITDA profit $6.8M; guides to full-year profitability","bullets":["Insurance revenue $341.7M (+7.8% YoY); total revenue $346.9M.","GAAP net loss from continuing ops improved to $23.2M from $79.7M loss in Q1 2023.","Adjusted EBITDA profit $6.8M versus loss $37.5M a year ago; Insurance MCR improved 870 bps to 77.9%.","Raised 2024 guidance: Insurance revenue $1.30B-$1.35B; Adj. EBITDA profitability $10M-$30M.","Board authorized $20M share repurchase over two years."],"urls":{"canonical":"https://secwatch.observer/filing/0001801170-24-000101","json":"https://secwatch.observer/filing/0001801170-24-000101.json","markdown":"https://secwatch.observer/filing/0001801170-24-000101.md","text":"https://secwatch.observer/filing/0001801170-24-000101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1801170/000180117024000101/0001801170-24-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1801170/000180117024000101/clov-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:38:26.522461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"718f780198d2c777078d80eab185568c604fd39a","claim":"CLOVER HEALTH INVESTMENTS, CORP. /DE reported the first quarter ended March 31, 2024 results: revenue $346.9 million, net income $23.2 million. Guidance raised.","evidence_excerpt":"exceeding its expectations on several key operating metrics and highlighting significant progress on its path to profitability. For the first quarter 2024, total revenue was $346.9 million, with GAAP net loss from continuing operations improving to $23.2 million. Adjusted EBITDA improved to a profit of $6.8 million, as compared to the prior year period loss of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1801170/000180117024000101/0001801170-24-000101-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$346.9 million"},{"label":"Net income","value":"$23.2 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}